> In early 1994, however, Green Cross ceased manufacturing Fluosol due to lack of interest from physicians and poor sales in their angioplasty indication (Table 25.1). Improvements in PTCA technology, notably the introduction of specialized autoperfusion catheters, made the need for Fluosol redundant.